Navigation Links
Gene Test May Help Predict Colon Cancer's Return
Date:2/17/2009

A marker in lymph nodes points to more persistent tumors, scientists say

TUESDAY, Feb. 17 (HealthDay News) -- A genetic test may better help survivors of colorectal cancer determine their risk of recurrence, a new study finds.

A report in the Feb. 18 issue of the Journal of the American Medical Association finds that guanylyl cyclase C (GUCY2C) -- an intestinal tumor-suppressing receptor in the lymph nodes -- may better reveal the chance of metastatic colorectal cancer.

According to researchers from Thomas Jefferson University in Philadelphia, doctors often biopsy the lymph nodes when trying to determine the prognosis of colorectal cancer. But when no cancer cells are found (a condition called pN0 colorectal cancer), the chance of recurrence is still about one in four. If cancer cells are found in four or more lymph nodes, the recurrence odds jump to one in two.

In studying 257 people with pN0 colorectal cancer, the team found that GUCY2C analysis "appeared to be an independent prognostic marker of risk." While conventional molecular staging techniques found 13 percent of patients were free of tumor cells, GUCY2C results suggested malignancy in 87 percent of cases.

Improved molecular staging "could overcome limitations in the detection of occult lymph node metastases," wrote the researchers.

The authors called for more studies with larger patient pools to better access the accuracy and reliably of the genetic test.

More information

The U.S. National Cancer Institute has more about colorectal cancer.



-- Kevin McKeever



SOURCE: Thomas Jefferson University, news release, Feb. 17, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Anti-social behavior in girls predicts adolescent depression seven years later
2. Urine Test May One Day Predict Prostate Cancer
3. Levels of Circulating Tumor Cells Could Predict Prostate Cancer Outcome
4. In Month of the Heart, Scientists Identify Better Way to Predict Heart-Disease Risk
5. MRI shows brain atrophy pattern that predicts Alzheimers
6. Gene Test Could Predict Thyroid Cancer Risk
7. Amyloid Beta Level in Serum Predicts Risk for Vascular Disease in First-Degree Relatives of Alzheimer's Patients
8. Protein predicts liver cancer recurrence and after transplantation
9. Rhythm abnormality of unknown origin strongly predicts sudden death risk in heart disease patients
10. Blood Test May Predict Postpartum Depression
11. Mental Illness Doesnt Predict Violent Behavior
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene Test May Help Predict Colon Cancer's Return 
Gene Test May Help Predict Colon Cancer's Return
(Date:12/5/2009)NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology int
(Date:12/5/2009)The MAMA campaign is a collaborative effort by the National Association of Certified Professional Midwives (NACPM), Midwives Alliance of North America (MANA), Citizens for Midwifery (CfM), Internation
(Date:12/4/2009)SAN FRANCISCO, Dec. 4 Medithrive, Inc. has won the Patient,s Choice Award as the favorite dispensary in the SF Bay Area by popular vote conducted by the online website, www.weedmaps.com. Despite on
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
Breaking Medicine News(10 mins):Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4
... , , , , Wheelock becomes chair, McNerney is v... EAGAN, Minn., Feb. 13 The Blue Cross and Blue Sh...as elected new board leaders. Pamela Wheelock, vic...cently held the position of vice chair. Wheelock h...
...nds even without weight loss, general health, func...thDay News) -- Even if it doesn,t help them lose w... quality of life, a U.S. study shows. , It include... expenditure of 4 kilocalories per kilogram (2.2 p...
...RTLAND, Oregon, Feb. 13 Women,s Healthcare Associ... midwifery, maternal fetal,medicine and genetics p... has,been honored by the American Academy of Nurse..., received the honor in a recent ceremony. America...
... - Dr. Tommy Tomizawa of UCLA Medical Center will ...cs may be beneficial to the elderly - , , TORRANC...ulation expected to climb over 300% in the next 50...mizawa, Assistant Professor at the David Geffen Me...
... highest ionized serum calcium 3 times more likely...(HealthDay News) -- A newly identified biomarker f... to decide whether or not to undergo treatment for...ith the lowest levels, said researchers at Wake Fo...
...E, Feb. 13 Seattle native composer Mateo Messina,... has recently won a Grammy award for Best Compilat... Other Visual Media. The team of talented artists ...es such as Juno and Thank You for Smoking to t...
Other Medicine News:Health News:Blue Cross Board of Trustees Elects New Leadership 2Health News:Exercise Boosts Quality of Life in Postmenopausal Women 2Health News:Women's Healthcare Associates Midwife Winner of American Academy of Nurse Practitioners State Award of Excellence 2Health News:The Effects of Probiotics on the Aging Digestive Tract to be Presented at Nutracon 2009 2Health News:Researchers ID Biomarker for Fatal Prostate Cancer 2Health News:Seattle Native Composer's Work Wins Grammy Award 2
(Date:12/4/2009)LAKE FOREST, Ill., Dec. 4 Hospira, Inc. (NYSE: HSP ), a leading global specialty pharmaceutical and medication delivery company, today announced the launch of its next-generation 50 mL and 100 mL V
(Date:12/4/2009)HOUSTON, Dec. 4 OrthoAccel Technologies, Inc., developers of the AcceleDent System , which is an acceleration device to enhance orthodontics, announced the availability of a new Continuing Education
(Date:12/4/2009)WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: AZN ) today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tab
Breaking Medicine Technology:Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Sono Tek Announces Second Quarter Results 5398 1Sono Tek Announces Second Quarter Results 5398 2Sono Tek Announces Second Quarter Results 5398 3AvMed Covers H1N1 Flu Vaccine For Members 5395 1AvMed Covers H1N1 Flu Vaccine For Members 5395 2Allscripts and Sandata Partner to Enhance Quality in Home Care Agencies Nationwide 10323 1Allscripts and Sandata Partner to Enhance Quality in Home Care Agencies Nationwide 10323 2Allscripts and Sandata Partner to Enhance Quality in Home Care Agencies Nationwide 10323 3
...LVERN, Pa., Nov. 18 Arlington Medical Resources (...r the pharmaceutical and diagnostic,imaging indust... Privigen was,sold in the U.S. during the third qu...ravenous immune globulin (IVIG) and was launched i...ated from the blood plasma of thousands,of donors ...
...ndomized study will enroll newly diagnosed, elderl...Celator Pharmaceuticals today announced that the f...e 2 clinical study of CPX-351 (Cytarabine:Daunorub...agnosed acute myeloid leukemia (AML). , , The... the Weill Medical College of Cornell University ...
Other Medicine Technology:Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
Medicine Products: